AstraZeneca PLC (AZN)vsNeurocrine Biosciences Inc (NBIX)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
NBIX
Neurocrine Biosciences Inc
$156.22
-0.22%
HEALTHCARE · Cap: $15.77B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1719% more annual revenue ($61.37B vs $3.37B). NBIX leads profitability with a 20.9% profit margin vs 17.0%. NBIX appears more attractively valued with a PEG of 0.31. NBIX earns a higher WallStSmart Score of 81/100 (A-).
AZN
Buy60
out of 100
Grade: C+
NBIX
Exceptional Buy81
out of 100
Grade: A-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Intrinsic value data unavailable for NBIX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Growing faster than its price suggests
Revenue surging 39.5% year-over-year
Safe zone — low bankruptcy risk
Keeps 21 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Strong operational efficiency at 22.2%
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : NBIX
The strongest argument for NBIX centers on PEG Ratio, Revenue Growth, Altman Z-Score. Profitability is solid with margins at 20.9% and operating margin at 22.2%. Revenue growth of 39.5% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : NBIX
The primary concerns for NBIX are Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while NBIX is a growth play — different risk/reward profiles.
NBIX carries more volatility with a beta of 0.38 — expect wider price swings.
NBIX is growing revenue faster at 39.5% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
NBIX scores higher overall (81/100 vs 60/100), backed by strong 20.9% margins and 39.5% revenue growth. AZN offers better value entry with a 18.4% margin of safety. Both earn "Exceptional Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Neurocrine Biosciences Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?